Comparison of the Pathogenesis of the Angola and Ravn Strains of Marburg Virus in the Outbred Guinea Pig Model

Journal of Infectious Diseases

Volumn 212, Issue , 2015, Pages S258-S270

  Cross, Robert W ^a,b   Fenton, Karla A ^a,b   Geisbert, Joan B ^a,b   Ebihara, Hideki ^c   Mire, Chad E ^a,b   Geisbert, Thomas W ^a,b  

^a Department of Microbiology and Immunology ^*  (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Angola; animal model; coagulation; filovirus; Guinea pig; Marburg virus; pathogenesis; Ravn

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; AMYLASE; ASPARTATE AMINOTRANSFERASE; CYTOKINE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; ICOSANOID; NITRIC OXIDE;

ADRENAL GLAND; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASOPHIL; BLOOD ANALYSIS; BLOOD CLOTTING; BODY WEIGHT; CONTROLLED STUDY; CYTOKINE PRODUCTION; EOSINOPHIL COUNT; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; GENE SEQUENCE; GENETIC SIMILARITY; GUINEA PIG MODEL; HIGH TEMPERATURE; HISTOPATHOLOGY; HYPOTHERMIA; IMMUNOHISTOCHEMISTRY; LETHALITY; LEUKOCYTE COUNT; LIVER; LUNG; LYMPHOCYTE COUNT; LYMPHOID TISSUE; MARBURGVIRUS; MARBURGVIRUS ANGOLA STRAIN; MARBURGVIRUS INFECTION; MARBURGVIRUS RAVN STRAIN; MONOCYTE; NEUTROPHIL COUNT; NONHUMAN; OUTBRED STRAIN; PALLOR; PATHOGENESIS; PHYLOGENY; PRIORITY JOURNAL; PROTHROMBIN TIME; SPECIES COMPARISON; SPLEEN; SPLEEN DISEASE; TEMPERATURE; THROMBOCYTE COUNT; UROGENITAL SYSTEM; VIREMIA; VIRUS GENOME; VIRUS INFECTION; VIRUS PATHOGENESIS; ANGOLA; ANIMAL; FEMALE; GENETIC LINKAGE; GENETIC VARIABILITY; GENETICS; GUINEA PIG; MARBURG HEMORRHAGIC FEVER; METABOLISM; PATHOGENICITY; PHYSIOLOGY; VIROLOGY; VIRULENCE;

ANGOLA; ANIMALS; BLOOD COAGULATION; CYTOKINES; FEMALE; GENETIC LINKAGE; GENETIC VARIATION; GUINEA PIGS; MARBURG VIRUS DISEASE; MARBURGVIRUS; NITRIC OXIDE; VIREMIA; VIRULENCE;

EID: 84943258198     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv182     Document Type: Article

References (32)

1. Colebunders R, Tshomba A, Van Kerkhove MD, et al. Marburg hemorrhagic fever in Durba and Watsa, Democratic Republic of the Congo: clinical documentation, features of illness, and treatment. J Infect Dis 2007; 196(suppl 2):S148-53.
2. Towner JS, Khristova ML, Sealy TK, et al. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J Virol 2006; 80:6497-516.
3. Johnson ED, Johnson BK, Silverstein D, et al. Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. Arch Virol Suppl 1996; 11:101-14.
4. Smith DH, Johnson BK, Isaacson M, et al. Marburg-virus disease in Kenya. Lancet 1982; 1:816-20.
5. Ursic-Bedoya R, Mire CE, Robbins M, et al. Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA. J Infect Dis 2014; 209:562-70.
6. Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, et al. Crossprotection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 2006; 80:9659-66.
7. Alves DA, Glynn AR, Steele KE, et al. Aerosol exposure to the angola strain of marburg virus causes lethal viral hemorrhagic Fever in cynomolgus macaques. Vet Pathol 2010; 47:831-51.
8. Geisbert TW, Daddario-DiCaprio KM, Geisbert JB, et al. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis 2007; 196(suppl 2):S372-81.
9. Warfield KL, Bradfute SB,Wells J, et al. Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol 2009; 83:6404-15.
10. Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine 2004; 22:3495-502.
11. Swenson DL, Warfield KL, Larsen T, Alves DA, Coberley SS, Bavari S. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines 2008; 7:417-29.
12. Wahl-Jensen V, Bollinger L, Safronetz D, de Kok-Mercado F, Scott DP, Ebihara H. Use of the Syrian hamster as a new model of ebola virus disease and other viral hemorrhagic fevers. Viruses 2012; 4:3754-84.
13. Thi EP, Mire CE, Ursic-Bedoya R, et al. Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA. Sci Transl Med 2014; 6:250ra116.
14. Ursic-Bedoya R, Mire CE, Robbins M, et al. Protection Against Lethal Marburg Virus Infection Mediated by Lipid Encapsulated Small Interfering RNA. J Infect Dis 2014; 209:562-70.
15. McElroy AK, Erickson BR, Flietstra TD, et al. Biomarker correlates of survival in pediatric patients with Ebola virus disease. Emerg Infect Dis 2014; 20:1683-90.
16. McElroy AK, Erickson BR, Flietstra TD, et al. Von Willebrand Factor Is Elevated in Individuals Infected with Sudan Virus and Is Associated with Adverse Clinical Outcomes. Viral Immunol 2015; 28:71-3.
17. Fisher-Hoch SP, Platt GS, Neild GH, et al. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J Infect Dis 1985; 152:887-94.
18. Geisbert TW, Young HA, Jahrling PB, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 2003; 163:2371-82.
19. Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 2000; 80:171-86.
20. Geisbert TW, Hensley LE, Larsen T, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003; 163:2347-70.
21. Bray M, Mahanty S. Ebola hemorrhagic fever and septic shock. J Infect Dis 2003; 188:1613-7.
22. Steinberg BE, Goldenberg NM, Lee WL. Do viral infections mimic bacterial sepsis? The role of microvascular permeability: A review of mechanisms and methods. Antiviral Res 2012; 93:2-15.
23. Bruegel M, Ludwig U, Kleinhempel A, et al. Sepsis-associated changes of the arachidonic acid metabolism and their diagnostic potential in septic patients. Crit Care Med 2012; 40:1478-86.
24. Feuerstein G, Hallenbeck JM. Prostaglandins, leukotrienes, and plateletactivating factor in shock. Annu Rev Pharmacol Toxicol 1987; 27: 301-13.
25. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005; 33:564-73.
26. Bae JS. Role of high mobility group box 1 in inflammatory disease: focus on sepsis. Arch Pharm Res 2012; 35:1511-23.
27. Lofts LL, Ibrahim MS, Negley DL, Hevey MC, Schmaljohn AL. Genomic differences between guinea pig lethal and nonlethal Marburg virus variants. J Infect Dis 2007; 196(suppl 2):S305-12.
28. Bamberg S, Kolesnikova L, Moller P, Klenk HD, Becker S. VP24 of Marburg virus influences formation of infectious particles. J Virol 2005; 79:13421-33.
29. Edwards MR, Johnson B, Mire CE, et al. The Marburg virus VP24 protein interacts with Keap1 to activate the cytoprotective antioxidant response pathway. Cell Rep 2014; 6:1017-25.
30. Albarino CG, Uebelhoer LS, Vincent JP, et al. Development of a reverse genetics system to generate recombinant Marburg virus derived from a bat isolate. Virology 2013; 446:230-7.
31. Albarino CG, Wiggleton Guerrero L, Spengler JR, et al. Recombinant Marburg viruses containing mutations in the IID region of VP35 prevent inhibition of Host immune responses. Virology 2014; 476C:85-91.
32. Fiddler RN. Collaborative study of modified AOAC method of analysis for nitrite in meat and meat products. J Assoc Off Anal Chem 1977; 60:594-9.